Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01931865 · ClinicalTrials.gov registry record · Phase 2
IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation
A Phase 2 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01931865 is a Phase 2 study that was terminated before completion, run by Yale University. The registered enrollment target is 12 participants.
The verdict
NCT01931865, a Phase 2 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this research study is to investigate the safety and effectiveness of botulinum toxin A (Xeomin) ® injections in patients who suffer from focal pain in areas of radiation and/or surgery as a result of cancer treatment. Our hypothesis is that injection of incobotulinum toxin A into an area of local pain, at or around the area of a post-surgical/post radiation scar, relieves the focal cancer pain.
Interventions
- DRUG IncobotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-09 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01931865
The ClinicalTrials.gov registry entry for NCT01931865 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IncobotulinumtoxinA is the first listed.
NCT01931865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01931865 about?
NCT01931865 is a clinical study titled "IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation". The purpose of this research study is to investigate the safety and effectiveness of botulinum toxin A (Xeomin) ® injections in patients who suffer from focal pain in areas of radiation and/or surgery as a result of cancer treatment. Our hypothesis is that injection of incobotulinum toxin A into an ...
What is the current status of trial NCT01931865?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2012-09. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01931865?
The interventions under investigation include: IncobotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT01931865?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.